Press release
Agitation in Alzheimer's Disease Market to Reach USD 8.6 Billion by 2034
Agitation in Alzheimer's Disease
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71893
With the global Alzheimer's population projected to triple by 2050, the management of agitation in AD has become a critical unmet need. Current treatments include antipsychotics, antidepressants, and off-label agents, but safety concerns and limited efficacy highlight the urgent need for novel therapies. Biopharma innovation, non-drug interventions, and precision diagnostics are driving the market forward.
Market Overview
• Market Size (2024): USD 4.9 billion
• Forecast (2034): USD 8.6 billion
• CAGR (2025-2034): 5.9%
Growth is supported by rising AD prevalence, regulatory approvals of new drugs, and increasing adoption of behavioral therapies and digital health solutions.
Key Highlights:
• Agitation affects up to 70% of Alzheimer's patients at some point in their disease.
• FDA approvals of drugs like brexpiprazole (for agitation in AD, 2023) create new market opportunities.
• Digital therapeutics and caregiver-support platforms expanding adoption.
• Growing investment in neuropsychiatric R&D pipelines.
Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Antipsychotics (Brexpiprazole, Risperidone, Quetiapine - limited use due to risks)
o Antidepressants (SSRIs such as Citalopram)
o Mood Stabilizers (Valproate, Carbamazepine - off-label)
o Benzodiazepines (short-term use, limited safety)
o Pipeline Agents (Novel NMDA modulators, serotonergic agents)
• Non-Pharmacological Interventions
o Cognitive Behavioral Therapy (CBT)
o Music Therapy, Light Therapy, Reminiscence Therapy
o Caregiver Training Programs
• Digital Health Solutions
o AI-Based Behavioral Monitoring
o Mobile Apps for Caregiver Support
o Virtual Reality (VR)-Based Calming Interventions
By Platform:
• Small Molecules (antipsychotics, antidepressants)
• Biologics (emerging monoclonals for neuroinflammation)
• Digital & Non-Pharma Interventions
By Technology:
• AI-Driven Neuropsychiatric Diagnostics
• Digital Biomarkers for Agitation
• Telemedicine & Remote Care Platforms
By End Use:
• Hospitals & Neurology Clinics
• Memory Care Centers
• Home Care Settings
• Research Institutes
By Application:
• Mild-to-Moderate Alzheimer's with Agitation
• Severe Alzheimer's with Agitation
• Clinical Research Trials
Segmentation Summary:
Pharmacological treatments remain dominant, but non-drug and digital health interventions are growing rapidly. Pipeline therapies targeting serotonergic and NMDA pathways represent the next wave of innovation.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71893/agitation-in-alzheimer-s-disease-market
Regional Analysis
North America
• Largest market with ~44% share in 2024.
• FDA approvals of brexpiprazole and ongoing clinical trials boosting adoption.
• High caregiver burden driving digital solution adoption.
Europe
• ~28% share.
• Germany, UK, and France leading in non-pharmacological therapy integration.
• EMA reviewing pipeline neuropsychiatric agents.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.1%.
• Rising AD prevalence in China, Japan, and India.
• Increasing government focus on dementia care infrastructure.
Middle East & Africa
• Smaller share but rising AD prevalence with aging populations.
• Limited specialized dementia care centers.
Latin America
• Brazil and Mexico driving regional adoption.
• Expanding access to generics and non-drug interventions.
Regional Summary:
North America leads with strong R&D and drug adoption, Europe excels in integrated care models, and Asia-Pacific grows fastest due to rapid demographic aging.
Market Dynamics
Key Growth Drivers:
• Rising global prevalence of Alzheimer's disease.
• FDA approvals of new agitation-specific therapies (e.g., brexpiprazole).
• Expanding digital health and caregiver support platforms.
• Growing focus on patient-centric, non-drug interventions.
Key Challenges:
• Safety concerns with antipsychotics and benzodiazepines.
• Limited efficacy of current therapies.
• High costs of specialized care.
• Underdiagnosis of BPSD in early Alzheimer's patients.
Latest Trends:
• Repurposing of psychiatric drugs for agitation in AD.
• Growth of digital therapeutics and VR-based calming tools.
• AI-driven behavioral monitoring for early intervention.
• Expansion of multi-modal care models integrating drug and non-drug therapies.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71893
Competitor Analysis
Major Players in the Market:
• Otsuka Pharmaceutical Co., Ltd. & Lundbeck A/S (Brexpiprazole - Rexulti)
• Eli Lilly and Company
• Johnson & Johnson
• Pfizer Inc.
• Roche Holding AG
• Biogen Inc.
• Novartis AG
• Axsome Therapeutics, Inc. (psychiatric pipeline therapies)
• Acadia Pharmaceuticals Inc.
• MindMaze (digital neurotherapeutics)
Competitive Summary:
Otsuka & Lundbeck lead with brexpiprazole approval, while Eli Lilly, Biogen, and Roche are investing in Alzheimer's pipelines. Axsome and Acadia are exploring psychiatric agents. MindMaze and other digital health firms are innovating in non-drug care. Competition centers on drug safety, pipeline efficacy, and digital health integration.
Conclusion
The Agitation in Alzheimer's Disease Market, valued at USD 4.9 billion in 2024, is projected to reach USD 8.6 billion by 2034, growing at a CAGR of 5.9%. Rising AD prevalence, new drug approvals, and digital health adoption will continue to shape the market.
Key Takeaways:
• Pharmacological therapies dominate, but non-drug and digital solutions are growing.
• North America leads due to FDA approvals and R&D pipelines.
• Europe excels in integrated dementia care models.
• Asia-Pacific grows fastest due to demographic aging and rising AD incidence.
• Multi-modal care models combining drugs, behavioral therapies, and digital tools will define the future.
The next decade will transform agitation in Alzheimer's disease care, moving from limited drug options to integrated precision therapies and digital health ecosystems, creating opportunities for pharma, biotech, and digital innovators alike.
This report is also available in the following languages : Japanese (アルツハイマー病市場の動揺), Korean (알츠하이머병 시장의 동요), Chinese (阿尔茨海默病市场的动荡), French (Agitation sur le marché de la maladie d'Alzheimer), German (Unruhe auf dem Alzheimer-Markt), and Italian (Agitazione nel mercato della malattia di Alzheimer), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71893/agitation-in-alzheimer-s-disease-market#request-a-sample
Our More Reports:
Intravenous Immunoglobulin Market
https://exactitudeconsultancy.com/reports/72414/intravenous-immunoglobulin-market
Radiopharmaceuticals Market
https://exactitudeconsultancy.com/reports/72413/radiopharmaceuticals-market
Veterinary Vaccines Market
https://exactitudeconsultancy.com/reports/72412/veterinary-vaccines-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Agitation in Alzheimer's Disease Market to Reach USD 8.6 Billion by 2034 here
News-ID: 4179529 • Views: …
More Releases from Exactitude Consultancy
Acute Pancreatitis Market is expected to reach USD 7.8 billion by 2034
Acute pancreatitis (AP) is a sudden inflammation of the pancreas that can range from mild, self-limiting episodes to severe, life-threatening disease. It is most commonly caused by gallstones, chronic alcohol use, hypertriglyceridemia, and certain medications. Symptoms include abdominal pain, fever, nausea, and in severe cases, multi-organ failure.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71891
AP is among the leading causes of gastrointestinal hospital admissions worldwide, contributing to high healthcare…
Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Market is expected to re …
Carbapenem-resistant Enterobacteriaceae (CRE) represent one of the most dangerous groups of multidrug-resistant (MDR) bacteria, including Klebsiella pneumoniae and Escherichia coli. These pathogens are resistant to nearly all available antibiotics, including carbapenems, which are considered last-resort treatments.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71765
CRE infections are associated with high mortality rates (up to 50%), prolonged hospital stays, and major economic burden. They occur most often in hospitalized, immunocompromised, and…
Campylobacter Infections Market is expected to reach USD 4.9 billion by 2034
Campylobacter infections, primarily caused by Campylobacter jejuni and Campylobacter coli, are among the leading causes of bacterial gastroenteritis worldwide. Transmission occurs mainly through contaminated food and water, especially undercooked poultry, unpasteurized milk, and untreated water sources. Symptoms include diarrhea (sometimes bloody), abdominal pain, fever, and in rare cases, severe complications such as Guillain-Barré syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71763
Despite being self-limiting in many cases, severe infections…
Bacterial meningitis market is expected to reach USD 11.1 billion by 2034
Bacterial meningitis is a severe, life-threatening infection of the meninges caused by pathogens such as Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, Group B Streptococcus, and Listeria monocytogenes. It progresses rapidly and can cause sepsis, neurological damage, or death if not treated promptly. Despite global vaccination efforts, the disease continues to pose a major public health challenge, particularly in low- and middle-income countries.
Download Full PDF Sample Copy of Market Report @…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
